Morgan Stanley maintains Jazz Pharmaceuticals at Overweight, raises price target to $319 from $314

What happened

Morgan Stanley kept its Overweight rating on Jazz Pharmaceuticals and raised its price target to $319 from $314, a 1.6% increase. That target implies 48.8% upside from the November 2 close of $214.44.

Confirmed

Global impact / market context

A higher target means this analyst sees more room for the share price to rise. That view can support investor demand for the stock, while the large gap to the target shows the market still prices in doubt about the company's outlook.

Analyst inference

Five recent analyst notes put targets from $275 to $314 before this raise. That range suggests broad agreement on value, while the new $319 target is now the highest of the group, which can draw attention to the stock.

Analyst inference

What to watch

1. Watch whether other analysts follow Morgan Stanley and raise their price targets, since five recent notes ranged from $275 to $314 before this move. Confirmed
2. Track future analyst notes and rating changes on Jazz Pharmaceuticals to see if the Overweight view is kept or changed over coming months. Proposed
3. Watch the share price relative to the $214.44 close, because closing part of the gap to $319 would show whether investors are acting on this analyst view. Analyst inference

Evidence

• Original source link unavailable